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Conclusion
Robust treatment effects were observed for both 70 mg and 140 mg
erenumab in subjects who had previously failed preventive migraine
treatments. For 140 mg, effects were numerically greater in this
subpopulation than in the overall trial population, and as in the overall
population, erenumab 140 mg showed numerically greater efficacy
than erenumab 70 mg. These results suggest that erenumab may have
particular utility in this subgroup of patients.
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Background
Current therapies for reducing raised intracranial pressure (ICP) in
conditions such as idiopathic intracranial hypertension have limited
efficacy and tolerability. As such, there is a pressing need to identify
novel drugs. Glucagon-like peptide-1 receptor (GLP-1R) agonists are
used to treat diabetes and promote weight loss but have also been
shown to affect fluid homeostasis in the kidney. Here, we investigate
whether exendin-4, a GLP-1R agonist, is able to modulate cerebro-
spinal fluid (CSF) secretion at the choroid plexus and subsequently
reduce ICP.
Methods
GLP-1R mRNA and protein was assessed by quantitative PCR,
immunohistochemistry and fluorescently tagged exendin-4 in human
and rat choroid plexus. The effect of exendin-4 on GLP-1R activation
and CSF secretion was evaluated in cultured rat choroid plexus epithe-
lial cells using cAMP assays and a Na+ K+ ATPase activity assay. The ef-
fect of Exendin-4 on ICP was assessed in adult female rats with normal
and raised ICP.
Results
We demonstrated that the GLP-1R is present in human and rat
choroid plexus. Exendin-4 significantly increased cAMP levels (2.14
± 0.61 fold, P<0.01) part of the GLP-1R signalling pathway, in a
concentration-dependant manner and this response could be inhib-
ited by the addition of the GLP-1R antagonist exendin 9-39.
Exendin-4 also significantly reduced Na+ K+ ATPase activity, a
marker of CSF secretion (39.3±9.4% of control; P<0.05). Finally,
in vivo ICP recording in female adult rats demonstrated that sub-
cutaneous administration of 20μg/kg exendin-4 significantly re-
duced ICP in normal (65.2 ± 6.6% of baseline; P<0.01) and raised
ICP rats (56.6 ± 5.7% of baseline; P<0.0001).
Conclusion
We demonstrate that exendin-4 reduces CSF secretion by the choroid
plexus, and ICP in normal rats and rats with raised ICP. Repurposing
existing GLP-1 drugs may represent a novel therapeutic strategy for
conditions of raised ICP such as idiopathic intracranial hypertension.
Additionally, GLP-1R agonist therapy promotes weight loss, which
would be advantageous in idiopathic intracranial hypertension.
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Background
Efficacy and safety/tolerability of erenumab, a human anti-CGRP re-
ceptor monoclonal antibody, were evaluated in episodic migraine
(EM) subjects in a multinational, phase 3 trial (NCT02456740).
Methods
Adults with EM (n=955) were randomised 1:1:1 to subcutaneous
monthly placebo or erenumab 70 mg or 140 mg for 24 weeks. The
primary endpoint was change from baseline in mean monthly
migraine days (MMDs) over weeks 13-24. Secondary endpoints were
≥50% reduction in MMDs; change in acute migraine-specific medica-
tion days; change in Physical Impairment (PI) and Impact on Every-
day Activities (EA) (as measured by the Migraine Physical Function
Impact Diary [MPFID]). P-values are for pairwise comparisons of each
erenumab dose with placebo, statistical significance determined after
multiplicity adjustment.
Results
Subjects reported 8.3 MMDs at baseline and experienced -3.2, -3.7,
and -1.8-day reductions in the 70 mg, 140 mg, and placebo groups,
respectively (p<0.001). A ≥50% reduction in MMDs was achieved by
43%, 50%, and 27% in the 70 mg, 140 mg, and placebo groups
(p<0.001), and monthly acute migraine- specific medication was
reduced by -1.1, -1.6, and -0.2 days (p<0.001). Subjects had
improved PI scores (-4.2, -4.8, -2.4 points in the 70 mg, 140 mg, and
placebo groups; p<0.001) and EA scores (-5.5, -5.9, and -3.3 points;
p<0.001). The safety/tolerability profile of erenumab was similar to
placebo; subjects most frequently reported nasopharyngitis, upper-
respiratory-tract infection, and sinusitis.
Conclusion
Erenumab 70 mg and 140 mg significantly reduced migraine frequency
and use of migraine-specific medications, reducing migraine’s impact
on physical impairment and everyday activities in this EM trial. Numer-
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Background
Cortical spreading depression (SD) is thought to underlie migraine
aura but mechanisms of triggering SD and propagation in the
structurally normal cortex of migraine patients is still unknown. Some
studies showed that the sensory predominance of migraine aura is
likely due to a greater susceptibility of primary sensory cortex to CSD
probably for their structural complexity [1]. We used MRI imaging
registration in migraine with aura patients to elaborate a CSD
propagation logarithm that takes into account the morphology of
the various cortical areas involved.
Materials and methods
We process the data sets with the Freesurfer software to obtain the
geometry and labelling for the different brain regions (Desikan-Kiliani
Atlas or Brodman areas 1, 2, 3, 4, 44, 45, 17, 18) in five migraine with
aura patients. According to the map of the disturbed areas suggested
by the aura symptoms, we then initialize the region first affected in the
respective hemisphere. Starting the propagation of the CSD in this
region we recorded the arrival time in each point of the brain cortex.
Results
We obtained the different brain geometries and the Brodman areas
1, 2, 3, 4, 44, 45, 17 and 18 of the five subjects. In order to run a
simulation of the CSD propagating on the cortex we need to identify
an initial region as a starting point for the wave. We take a bearing
on the map of the disturbed regions provided along with the MRI
data from the patients. For the simulation of the CSD we started the
wave in these regions and recorded the propagation. In each point
we recorded the arrival time of the wave. We visualize the arrival
times of the wave in the Fig. 1. This was in accord with the reported
evolution of the clinical symptoms.
Conclusions
The way CSD propagates can change in relation to brain morphology.
The specific algorithm was able to provide for a simulation of the
electrical phenomenon, explaining the progressive evolution of clinical
symptoms. Further tests in larger series, could give an aid in
understanding the pathophysiological peculiarities of migraine-with-aura
brain.
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Interventional treatment is an important but underevaluated issue for
neurologist. However peripheral nerve blocks have been used for both
acute and preventive treatment of headaches for decades and are safe
and effective therapeutic options for many patients with headache
disorders. They can cause a long lasting (several weeks to months) pain
relief. This long lasting effect is thougt to be due to central pain
modulation. Nerve blocks may be an option for the patients who have
failed their home medications or who doesn’t want to use drugs.
Blocks may also be used to treat patients who need relief between
onabotulinum toxin A injections and in medication overuse headache
during their acute therapy. Nerve blocks are safe and can be
appropriate for children and pregnant patients, and also in patients
with kidney-liver diseases. In pregnancy, lidocaine is considered a cat-
egory B drug. Greater occipital nerve blockade is the most common
procedure in peripheral nerve blocks. But lesser occipital nerve block-
ades, sphenopalatine ganglion blockades, supratrochlear, auriculotem-
poral, supraorbital, infraorbital and mental nerve blockades, cervical
root blockades, their combinations can be used in patients with head-
ache disorders. Local anestetics and steroids are being used for nerve
blockades.
Botulinum toxin injections are also approved effective methods for
migraine all over the World. There is some other indications under
search and experineces increases the applications in every day.
We want to show the injection techniques and efficacy by sharing
our cases. Deepending on the time, after the presentation some
audience keep a chance to applicate tehmselves on the model
provided by authors.
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Background
A study was conducted to determine if galcanezumab (120 or 240
mg monthly), a humanized monoclonal antibody that selectively
binds to calcitonin gene-related peptide, was superior to placebo in
the prevention of chronic migraine.
Materials and methods
Eligible patients 18-65 years of age with chronic migraine (≥15 head-
ache days per month, of which at least 8 met criteria for migraine) were
randomized 2:1:1 to subcutaneous monthly injections of placebo
(N=558), galcanezumab 120 (N=278) or 240 mg (N=277). The primary
endpoint was the overall mean change-from-baseline in the number of
monthly migraine headache days (MHD) during the 3-month double-
blind treatment period. Key secondary measures included rates of
≥50%, ≥75%, and 100% reduction in monthly MHD, as well as the
changes in monthly MHD with acute migraine treatments, the Role
Function-Restrictive domain score of the Migraine-Specific Quality of
Life Questionnaire (MSQ-RFR), and the Patient Global Impression-
Severity of Illness (PGI-S).
Fig. 1 (abstract O4). Simulation of CSD progression in a single
patient with reported scotomas in the right visual hemifield,
followed by bilateral brachial paresthesia and speech disturbances.
The time of progressive cortical areas involvement in the simulation
model, was in accord with the reported clinical evolution of aura
symptoms.
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